Intra-tumor combination of SLC and anti-CD25 mAb is an effective method for the treatment of HCC, which is related to the change of tumor microenvironment and the systematic optimization percentage of Treg, CD8+ T cells and CD4+ T cells in peripheral immune organs. This evidence concerns the gene CD8A and hepatocellular carcinoma.